133 related articles for article (PubMed ID: 22070369)
21. Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome.
Kebapcilar L; Taner CE; Kebapcilar AG; Alacacioglu A; Sari I
Arch Gynecol Obstet; 2010 Jan; 281(1):35-42. PubMed ID: 19330342
[TBL] [Abstract][Full Text] [Related]
22. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
23. The effects of desogestrel and ethinylestradiol combination in normal and hyperandrogenic young girls: speculations on contraception in adolescence.
Venturoli S; Porcu E; Gammi L; Fabbri R; Paradisi R; Flamigni C; Patrono D; Capelli M; Paoletti C
Acta Eur Fertil; 1988; 19(3):129-34. PubMed ID: 2976224
[TBL] [Abstract][Full Text] [Related]
24. Body fat composition and distribution in women with polycystic ovary syndrome.
Cosar E; Uçok K; Akgün L; Köken G; Sahin FK; Arioz DT; Baş O
Gynecol Endocrinol; 2008 Aug; 24(8):428-32. PubMed ID: 18850379
[TBL] [Abstract][Full Text] [Related]
25. The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women.
Nader S; Riad-Gabriel MG; Saad MF
J Clin Endocrinol Metab; 1997 Sep; 82(9):3074-7. PubMed ID: 9284746
[TBL] [Abstract][Full Text] [Related]
26. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome.
Loverro G; Lorusso F; De Pergola G; Nicolardi V; Mei L; Selvaggi L
Gynecol Endocrinol; 2002 Jun; 16(3):217-24. PubMed ID: 12192894
[TBL] [Abstract][Full Text] [Related]
27. Insulin resistance and overweight-obese women with polycystic ovary syndrome.
Bhattacharya SM
Gynecol Endocrinol; 2010 May; 26(5):344-7. PubMed ID: 19903118
[TBL] [Abstract][Full Text] [Related]
28. Effect of ethinylestradiol/cyproterone acetate on endothelial function in young non-obese women with polycystic ovary syndrome: a pilot study.
Naka KK; Kalantaridou SN; Bechlioulis A; Kravariti M; Kazakos N; Katsouras CS; Tsatsoulis A; Michalis LK
Gynecol Endocrinol; 2011 Sep; 27(9):615-21. PubMed ID: 21329419
[TBL] [Abstract][Full Text] [Related]
29. Effects of drospirenone pill in Indian women with polycystic ovary syndrome.
Bhattacharya SM; Ghosh M; Nandi N
J Turk Ger Gynecol Assoc; 2011; 12(3):144-7. PubMed ID: 24591981
[TBL] [Abstract][Full Text] [Related]
30. SHBG, testosterone, androstenedione, 17-OH-Progesterone plasma levels in PCO affected women treated with a triphasic oral contraceptive.
Negri P; Agnello G; Borghesani F; Tomain L; Minisci N; D'Errico G; Cavallini AR
Acta Eur Fertil; 1987; 18(6):375-80. PubMed ID: 3454501
[TBL] [Abstract][Full Text] [Related]
31. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome.
Shi Y; Guo M; Yan J; Sun W; Zhang X; Geng L; Xu L; Chen Z
Neuro Endocrinol Lett; 2007 Dec; 28(6):807-10. PubMed ID: 18063948
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism.
Batukan C; Muderris II
Fertil Steril; 2006 Feb; 85(2):436-40. PubMed ID: 16595223
[TBL] [Abstract][Full Text] [Related]
33. Effects of ethinyl estradiol-cyproterone acetate treatment on metabolic syndrome, fat distribution and carotid intima media thickness in polycystic ovary syndrome.
Karabulut A; Demirlenk S; Sevket O
Gynecol Endocrinol; 2012 Apr; 28(4):245-8. PubMed ID: 21961995
[TBL] [Abstract][Full Text] [Related]
34. [Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome].
Ye BL; Yang HY; Zhao JZ; Lin JJ; Lin WQ
Zhonghua Fu Chan Ke Za Zhi; 2003 Dec; 38(12):745-8. PubMed ID: 14728846
[TBL] [Abstract][Full Text] [Related]
35. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome.
Kriplani A; Agarwal N
J Reprod Med; 2004 May; 49(5):361-7. PubMed ID: 15214709
[TBL] [Abstract][Full Text] [Related]
36. [Changes in plasma levels of androgens and SHBG in patients with polycystic ovary syndrome (PCOs) treated with oral contraceptives containing desogestrel].
Negri P; D'Errico G; Minisci N; Tomasi A
Minerva Ginecol; 1988 Dec; 40(12):699-707. PubMed ID: 2977429
[TBL] [Abstract][Full Text] [Related]
37. [Efficacy and metabolic safety of long-term treatment with ethinyl oestradiol/cyproterone and desogestrel/ethinyl oestradiol tablets in women with polycystic ovary syndrome].
Zhang J; Su M; Xu L; Yang Z; Yin W; Nie Y; Qiao X; Cheng R; Ma Y
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Jul; 38(8):917-922. PubMed ID: 30187872
[TBL] [Abstract][Full Text] [Related]
38. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
Fruzzetti F; Perini D; Lazzarini V; Parrini D; Gambacciani M; Genazzani AR
Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
[TBL] [Abstract][Full Text] [Related]
39. Insulin resistance is not strictly associated with energy intake or dietary macronutrient composition in women with polycystic ovary syndrome.
Toscani MK; Mario FM; Radavelli-Bagatini S; Spritzer PM
Nutr Res; 2011 Feb; 31(2):97-103. PubMed ID: 21419313
[TBL] [Abstract][Full Text] [Related]
40. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Kazerooni T; Dehghan-Kooshkghazi M
Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
